NewLink Genetics Corporation (NASDAQ: NLNK) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare NewLink Genetics Corporation to similar businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
Earnings & Valuation
This table compares NewLink Genetics Corporation and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NewLink Genetics Corporation||$35.77 million||-$85.15 million||-3.65|
|NewLink Genetics Corporation Competitors||$213.37 million||-$39.02 million||-66.12|
This is a summary of current ratings and recommmendations for NewLink Genetics Corporation and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NewLink Genetics Corporation||0||0||6||0||3.00|
|NewLink Genetics Corporation Competitors||507||2375||6540||121||2.66|
NewLink Genetics Corporation currently has a consensus price target of $25.67, indicating a potential upside of 188.07%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.96%. Given NewLink Genetics Corporation’s stronger consensus rating and higher probable upside, equities research analysts clearly believe NewLink Genetics Corporation is more favorable than its peers.
This table compares NewLink Genetics Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NewLink Genetics Corporation||-229.19%||-63.39%||-47.83%|
|NewLink Genetics Corporation Competitors||-3,402.40%||-542.90%||-40.80%|
Insider & Institutional Ownership
46.1% of NewLink Genetics Corporation shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.7% of NewLink Genetics Corporation shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
NewLink Genetics Corporation has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, NewLink Genetics Corporation’s peers have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
What are top analysts saying about NewLink Genetics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NewLink Genetics Corporation and related companies.